文献速递冠心病

ISCHEMIA试验:初始侵入与初始保守策略对复发和总心血管事件的影响

Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial.
PubMed 文献 · Eur Heart J · 2022-01-01

ISCHEMIA试验预设分析,纳入5179例稳定冠心病伴中重度心肌缺血患者,随机接受初始侵入或初始保守管理。采用Ghosh-Lin方法估计以死亡为竞争风险的总事件平均累积发生率。结果显示初始侵入策略在预防净复发事件或净总事件方面未优于初始保守策略。

要点

  • 稳定冠心病伴中重度缺血患者中,初始侵入策略未减少复发或总心血管事件。
  • 每100例患者4年平均主要终点事件数:侵入组18.2,保守组19.7,差异无统计学意义。
  • 有复发事件的患者年龄更大,高血压、糖尿病、既往心梗或脑血管病及多支病变更常见。

核心结论

  • 在ISCHEMIA试验的稳定冠心病伴中重度心肌缺血患者中,初始侵入治疗策略在预防净复发事件或净总事件方面未比初始保守策略更有效。

研究设计与样本

  • ISCHEMIA试验的预设分析,纳入5179例稳定冠心病伴负荷试验中重度缺血患者,随机分为初始侵入组或初始保守组。
  • 主要终点为心血管死亡、心肌梗死、因不稳定性心绞痛、心力衰竭或心脏骤停住院的复合终点。
  • 采用Ghosh-Lin方法估计以死亡为竞争风险的总事件平均累积发生率。

主要发现

  • 5179例患者共发生670例次索引事件(侵入组318,保守组352)和203例次复发事件(侵入组102,保守组101)。
  • 发生1次主要事件的患者比例:侵入组9.8%,保守组10.8%;发生≥2次主要事件的比例分别为2.5%和2.8%。
  • 每100例患者4年平均主要终点事件数:侵入组18.2(95%CI 15.8-20.9),保守组19.7(95%CI 17.5-22.2),差异-1.5(95%CI -5.0至2.0,P=0.398)。
  • 以全因死亡替代心血管死亡或将卒中加入事件后,结果相似。

临床怎么用

  • 对于稳定冠心病伴中重度心肌缺血患者,初始侵入策略不应以减少复发或总心血管事件为目的而常规选择。
  • 临床决策应综合评估患者症状、缺血负荷及合并症,而非仅期望通过初始侵入降低事件复发。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial prespecified an analysis to determine whether accounting for recurrent cardiovascular events in addition to first events modified understanding of the treatment effects. METHODS AND RESULTS: Patients with stable coronary artery disease (CAD) and moderate or severe ischaemia on stress testing were randomized to either initial invasive (INV) or initial conservative (CON) management. The primary outcome was a composite of cardiovascular death, myocardial infarction (MI), and hospitalization for unstable angina, heart failure, or cardiac arrest. The Ghosh-Lin method was used to estimate mean cumulative incidence of total events with death as a competing risk. The 5179 ISCHEMIA patients experienced 670 index events (318 INV, 352 CON) and 203 recurrent events (102 INV, 101 CON). A single primary event was observed in 9.8% of INV and 10.8% of CON patients while ≥2 primary events were observed in 2.5% and 2.8%, respectively. Patients with recurrent events were older; had more frequent hypertension, diabetes, prior MI, or cerebrovascular disease; and had more multivessel CAD. The average number of primary endpoint events per 100 patients over 4 years was 18.2 in INV [95% confidence interval (CI) 15.8-20.9] and 19.7 in CON (95% CI 17.5-22.2), difference -1.5 (95% CI -5.0 to 2.0, P = 0.398). Comparable results were obtained when all-cause death was substituted for cardiovascular death and when stroke was added as an event. CONCLUSIONS: In stable CAD patients with moderate or severe myocardial ischaemia enrolled in ISCHEMIA, an initial INV treatment strategy did not prevent either net recurrent events or net total events more effectively than an initial CON strategy. CLINICAL TRIAL REGISTRATION: ISCHEMIA ClinicalTrials.gov number, NCT01471522, https://clinicaltrials.gov/ct2/show/NCT01471522.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lopez-Sendon JL, Cyr DD, Mark DB, et al. Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. Eur Heart J. 2022. PMID: 34514494. doi:10.1093/eurheartj/ehab509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。